MAPT and Alzheimer disease: Prior to the onset of AD, individuals may present with either preclinical AD, defined by the absence of clinical symptoms but positive disease biomarkers such as amyloid and tau proteins in the cerebral spinal fluid (CSF), [3] or they may present with mild cognitive impairment (MCI), defined by mild impairment on neurocognitive testing that does not affect activities of daily living [4].